These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1234 related articles for article (PubMed ID: 19509181)

  • 1. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids.
    Krishan A; Sharma D; Sharma S; Hamelik RM; Ganjei-Azar P; Nadji M
    Cytometry B Clin Cytom; 2010 May; 78(3):176-82. PubMed ID: 20043317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
    Abraham BK; Fritz P; McClellan M; Hauptvogel P; Athelogou M; Brauch H
    Clin Cancer Res; 2005 Feb; 11(3):1154-9. PubMed ID: 15709183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
    Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
    Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer.
    Theodoropoulos PA; Polioudaki H; Agelaki S; Kallergi G; Saridaki Z; Mavroudis D; Georgoulias V
    Cancer Lett; 2010 Feb; 288(1):99-106. PubMed ID: 19619935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
    Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy.
    Aulmann S; Waldburger N; Penzel R; Andrulis M; Schirmacher P; Sinn HP
    Hum Pathol; 2010 Apr; 41(4):574-81. PubMed ID: 20004947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
    Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
    Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
    Croker AK; Allan AL
    Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
    Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
    Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
    Bauerschmitz GJ; Ranki T; Kangasniemi L; Ribacka C; Eriksson M; Porten M; Herrmann I; Ristimäki A; Virkkunen P; Tarkkanen M; Hakkarainen T; Kanerva A; Rein D; Pesonen S; Hemminki A
    Cancer Res; 2008 Jul; 68(14):5533-9. PubMed ID: 18632604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.